Insuman Comb 25 Solostar (Insulin Human (Rdna))

Insulin Human mimics the action of naturally produced insulin by binding to insulin receptors on muscle, fat and liver cells. This binding activates intracellular pathways that increase glucose uptake, stimulate glycogen synthesis, and suppress hepatic glucose output, thereby lowering circulating blood glucose concentrations.

The dosage of Insuman Comb 25 Solostar is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, type of diabetes, current glycemic control, diet, and other medications. Patients should follow the prescribing healthcare professional’s instructions and not adjust the dose on their own.

Safety data for Insuman Comb 25 Solostar in pregnancy and lactation are limited, and the product’s pregnancy category is unknown. It should only be used if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Insuman Comb 25 Solostar is a premixed human insulin containing a fixed ratio of intermediate‑acting and rapid‑acting components. Compared with basal‑only insulins, it offers both background and mealtime coverage in a single injection, reducing the number of daily shots. Unlike some analog insulins, it uses recombinant human insulin, which may be preferred for patients seeking a biosimilar option.

The pen should be stored at 2‑8 °C (refrigerated) and protected from light. Do not freeze or shake the device. Once in use, it may be kept at room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label. Always keep the pen in its original packaging to maintain sterility.

Insuman Comb 25 Solostar is delivered subcutaneously using the pre‑filled pen. The injection site should be rotated among the abdomen, thigh or upper arm to reduce lipodystrophy. Patients should clean the skin with an alcohol swab, attach a new needle, set the prescribed dose, and inject at a 90‑degree angle. Proper technique should be taught by a healthcare professional.

The most serious risks include severe hypoglycemia, which can cause seizures, loss of consciousness or injury, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical help if an allergic response occurs.

Insuman Comb 25 Solostar should be avoided in individuals with known hypersensitivity to human insulin or any excipients in the formulation. It is also contraindicated in patients experiencing active hypoglycemia. Caution is advised for those with severe renal or hepatic impairment, and the product should be used only under medical supervision in such cases.